Our recent studies showed that pretreatment of these transgenic mice with
one of 3 new experimental drugs including NIPRISAN[19], MX-1520
[20], and 5-hydroxymethyl-2-furfural (5HMF) [21]reduced the percentage of POSCs in the venous circulation, inhibited the conversion of
flexible POSCs to rigid PDSCs, inhibited the development of pulmonary
sequestration, and prolonged the survival time of the mice under severe
acute hypoxic conditions (5% O2/95% N2) in a dose-dependent manner.
Further investigation is necessary to study thein vivorelationship between POSCs and the severity of SCD.